Description:
Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest.
- Molecular Weight: 447.53
- Molecular Formula: C24H29N7O2
Purity: >95%
Canonical SMILES:
CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
InChI:
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
InChIKey: AHJRHEGDXFFMBM-UHFFFAOYSA-N
- Boiling Point: 711.5±70.0°C at 760 mmHg
- Melting Point: >244°C (dec.)
- Solubility: Soluble in Chloroform (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated)
- Appearance: Pale Yellow to Green Solid
- Storage: Store at 2-8°C
Synonyms:
PD 0332991; PD0332991; PD-0332991; Ibrance; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
More details are to be found on supplier website
